The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

FDA APPROVAL OF IND FOR THE GROUP'S PRODUCT UBT48128 TABLETS

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the Investigational New Drug ("IND") applications for UBT48128 Tablets, a Class 1 new drug self-developed by The United Bio-Technology (Hengqin) Co., Ltd., a wholly-owned subsidiary of the Company, for the indications of overweight or obesity and type 2 diabetes have been approved by the U.S. Food and Drug Administration ("FDA"), with IND numbers 182060 and 182061, respectively.

UBT48128 Tablets is a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist that lowers blood glucose and promotes weight loss by stimulating insulin secretion while regulating appetite and energy metabolism. Preclinical studies in multiple animal models have demonstrated that UBT48128 significantly reduces body weight and blood glucose levels, with superior weight-loss efficacy compared to currently marketed products in the same category. This product is expected to demonstrate favorable therapeutic benefits in the treatment of overweight or obesity and type 2 diabetes.

Moving forward, the Company will continue to advance the research and development of new products, strengthen its competitiveness and innovation in the biopharmaceutical industry, and focus on chronic disease treatment by delivering higher-quality products and a robust pipeline to serve clinical practice and benefit patients, which is expected to generate greater value for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 11 August 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.